COX-2 Enzymes Modulate DNA Damage
Study Provides Insights Into COX-2 Inhibitors’
(Boston, MA) - In an ongoing effort to understand the
link between oxidative stress and cancer, Ian
Blair, PhD, Director of the Center for Cancer
Pharmacology at the University of Pennsylvania
School of Medicine, and colleagues have discovered
the first evidence in cells that cyclooxygenase-2 enzymes
(COX-2) can cause DNA damage and that the inhibition
of that damage may be important in preventing cancer.
Blair will report these findings at the annual meeting
of the American Society for Biochemistry and Molecular
Biology (ASBMB)/8th International Union of Biochemistry
and Molecular Biology Conference in Boston. He will
participate in a press briefing at the meeting starting
at 11:00 EST, Tuesday June 15.
Using cells transfected with COX-2 developed at Vanderbilt
University, Blair and his team showed that COX-2 can
cause DNA damage. “This now makes the link between
cyclooxygenases, lipid hydroperoxides, and DNA damage,”
says Blair. During oxidative stress, lipids are oxidized
to form molecules called lipid hydroperoxides, which
in turn degrade to highly reactive compounds called
genotoxins. These genotoxins bind to DNA and cause mutations.
A number of studies are ongoing in Blair’s and
other labs to look at the effect of COX-2 inhibitors
on cancerous cell growth. COX-2 inhibitors are now the
basis of such pain and inflammation medications as Vioxx
In a previous study, Blair and his lab found that vitamin
C, an antioxidant, can increase the formation of genotoxins
resulting from the oxidation of lipids. In this present
study, they showed that this activity also occurs in
Under normal conditions, lipid hydroperoxides break
down so quickly that they never degrade into genotoxins.
But during oxidative stress -- when natural antioxidants
within the body fail to mop up damaging molecules --
genotoxins build up and cause DNA damage. Genotoxins
chemically bond to DNA, thereby changing its structure.
When DNA is being replicated the resulting mutations
cause widespread mistakes in the production of proteins
and cell death.
Genotoxins carry the effect of a double-edged sword.
“In the case of chemotherapy when a genotoxin
binds to DNA, the cell signals for that tumor cell to
die,” explains Blair. But genotoxins can have
deleterious effects in that they also cause mutations
in normal cells.
A new method for the analysis of DNA damage in these
cells was developed by Seon Hwa Lee, a Research Associate
in Pharmacology, and Michelle Williams, a student in
the Graduate Group in Pharmacological Sciences.
This work points to another way to prevent cancer-drugs
that remove COX-2-associated genotoxins. Many studies
have shown that diets high in fruits, grains, and vegetables
may reduce cancer risk, and now Blair’s group
is looking for micronutrients in these foods that are
able to remove COX-2 genotoxins. “There are many
levels at which you can protect against DNA damage,”
says Blair. “What our work has done is to focus
attention on the fact that it’s not just a single
magic bullet, that a good diet is better than just taking
loads of vitamin pills.”
a printer friendly version of this release, click
PENN Medicine is a $2.5 billion enterprise dedicated to
the related missions of medical education, biomedical
research, and high-quality patient care. PENN Medicine
consists of the University of Pennsylvania School of
Medicine (founded in 1765 as the nation’s first
medical school) and the University of Pennsylvania Health
System (created in 1993 as the nation’s first
integrated academic health system).
Penn’s School of Medicine is ranked #3 in the
nation for receipt of NIH research funds; and ranked
#4 in the nation in U.S. News & World Report’s
most recent ranking of top research-oriented medical
schools. Supporting 1,400 fulltime faculty and 700 students,
the School of Medicine is recognized worldwide for its
superior education and training of the next generation
of physician-scientists and leaders of academic medicine.
Penn Health System consists of four hospitals (including
its flagship Hospital of the University of Pennsylvania,
consistently rated one of the nation’s “Honor
Roll” hospitals by U.S. News & World Report),
a faculty practice plan, a primary-care provider network,
three multispecialty satellite facilities, and home
health care and hospice.
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $6.7 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $392 million awarded in the 2016 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center -- which are recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report -- Chester County Hospital; Lancaster General Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2016, Penn Medicine provided $393 million to benefit our community.